CVI Holdings’s Revelation Biosciences REVB Stock Holding History

CVI Holdings’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$43.2K	–	296
2023 Q1	$43.2K	Buy	+6	New	+$162K	0.02%	177
2021 Q4	–	Sell	-1	Closed	-$3.02M	–	973
2021 Q3	$3.02M	Hold	1	–	–	0.19%	181
2021 Q2	$3M	Hold	1	–	–	0.2%	164
2021 Q1	$3M	Buy	+1	New	+$2.05M	0.21%	154

Other funds holding REVB

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CVI Holdings's REVB Position: Q2 2023 in Review

CVI Holdings sold out of Revelation Biosciences (REVB) in Q2 2023, closing a stake of 6 shares — an estimated $43.2K sold.

CVI Holdings first reported a position in REVB in Q1 2021 and held it in 4 quarters. The position peaked at $3.02M in Q3 2021. 5 funds tracked by Wall St. Rank hold REVB as of Q2 2023.

CVI Holdings reported no remaining Revelation Biosciences position as of Q2 2023 after selling out during the quarter.
CVI Holdings sold 6 Revelation Biosciences shares in Q2 2023, an estimated $43.2K.
CVI Holdings first reported a position in Revelation Biosciences in Q1 2021 and held it in 4 quarters.
CVI Holdings's Revelation Biosciences position peaked at $3.02M in Q3 2021.
5 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2023.

Based on CVI Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.